HSIN-MING CHENChen C.-T.HSIANG YANGYEN-PING KUOKuo Y.-S.Lan W.-H.YI-PING WANGTsai T.CHUN-PIN CHIANG2021-10-182021-10-1820041368-8375https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842424985&doi=10.1016%2fj.oraloncology.2003.12.010&partnerID=40&md5=5c23f67d97f69437ecd98985de07b747https://scholars.lib.ntu.edu.tw/handle/123456789/585081Previous studies have shown a selective accumulation of 5-aminolevulinic acid (ALA)-derived protoporphrin IX (PpIX) in oral premalignant and malignant tissues. This provides a biologic rationale for the clinical use of ALA-mediated PDT (ALA-PDT) for oral premalignant and malignant lesions. In this study, five patients with oral verrucous hyperplasia (OVH) were treated with a new protocol of ALA-PDT composed of multiple 3-min irradiations with a light emitting diode (LED) red light at 635±5 nm separated with several 3-min rests for a total of 1000 s (fluence rate, 100 mW/cm2; light exposure dose, 100 J/cm2) after topical application of 20% ALA for 1.5 or 2 h. Topical ALA-PDT was repeated once a week until the complete regression of the lesion. Complete regression of all OVH lesions was observed after 1-3 treatments (average, 2 treatments) of topical ALA-PDT. At an average follow-up of 5.6 months (range, 3-11 months), all the five OVH patients were free of tumor recurrence. We conclude that topical ALA-PDT with fractionated irradiations by an LED red light at 635±5 nm is an effective and successful treatment modality for OVH. ? 2004 Elsevier Ltd. All rights reserved.[SDGs]SDG3aminolevulinic acid; analgesic agent; carbomer; carbopol 971p; poloxamer; protoporphyrin; unclassified drug; adult; article; cancer radiotherapy; cancer regression; clinical article; clinical protocol; clinical trial; controlled clinical trial; controlled study; drug efficacy; drug formulation; follow up; human; human tissue; leukoplakia; light emitting diode; male; oral verrucous hyperplasia; pain; photodynamic therapy; priority journal; radiation dose; red light; treatment outcome; tumor recurrence; Adult; Aminolevulinic Acid; Humans; Hyperplasia; Male; Middle Aged; Mouth Diseases; Mouth Neoplasms; Photochemotherapy; Photosensitizing Agents; Precancerous Conditions; Spectrometry, Fluorescence; Treatment Outcome; Wartsjournal article10.1016/j.oraloncology.2003.12.010150633922-s2.0-1842424985